Skip to main content
NIH funding notice PA-18-158

Applying Metabolomics to Drive Biomarker Discovery in Symptom Science (R21 Clinical Trial Optional)

Closed on May 7, 2019.

Posted
November 6, 2017
Close date
May 7, 2019
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $726,145 in first-year total cost, median $228,895.

Most frequent study sections

  1. Clinical and Integrative Cardiovascular Sciences Study Section[CICS]1
  2. Hypertension and Microcirculation Study Section[HM]1
  3. Neuroendocrinology, Neuroimmunology, Rhythms and Sleep Study Section[NNRS]1

Most frequent institutions

  1. BRIGHAM AND WOMEN'S HOSPITAL1
  2. TUFTS UNIVERSITY BOSTON1
  3. UNIVERSITY OF FLORIDA1
Competing awards under PA-18-158 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2019Urine metabolomics to estimate internal clock time1R21NR018974-01ST HILAIRE, MELISSA APRILBRIGHAM AND WOMEN'S HOSPITAL, MA$268,500NNRS
2019Gut-brain axis: functional link between microbial metabolites and neurogenic hypertension1R21AT010192-01MARTYNIUK, CHRISTOPHER JOSEPHZUBCEVIC, JASENKAUNIVERSITY OF FLORIDA, FL$228,750HM
2018Diagnosis of Heart Failure Status using Epidermal Metabolomics1R21NR017704-01A1BALEJA, JAMES DTUFTS UNIVERSITY BOSTON, MA$228,895CICS

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PA-18-158: Applying Metabolomics to Drive Biomarker Discovery in Symptom Science (R21 Clinical Trial Optional) | ScienceDex | ConductScience